CytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast Cancer
Both studies will start leronlimab at 700mg and assess dose reductions using a 21-day dose-limiting toxicity observation period.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CytoDyn (OTCQB: CYDY) announced plans to evaluate leronlimab in two new metastatic triple-negative breast cancer regimens within QLHC’s PRE-I-SPY platform.
The Phase 1-1b studies will primarily assess safety and tolerability, alongside preliminary clinical activity and exploratory biomarkers. PRE5 will combine leronlimab with Merck’s pembrolizumab and sacituzumab; PRE7 will combine it with Akeso’s penpulimab, gemcitabine and carboplatin. CytoDyn expects PRE5 enrollment in the first quarter of 2027; PRE7 enrollment is likely in the second or third quarter of 2027. PRE5 will primarily enroll first- or second-line patients, while PRE7 will focus on second-line patients. Both will include patients with PD-L1 combined positive scores below 10, a measure of biomarker expression. QLHC sponsors the platform, and CytoDyn will provide leronlimab.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.PRE5 will evaluate leronlimab with pembrolizumab and sacituzumab; CytoDyn expects enrollment in the first quarter of 2027.
- Moderate point. Forward-looking: it has not happened yet and may not happen.PRE7 will evaluate leronlimab with penpulimab, gemcitabine and carboplatin; enrollment is likely in the second or third quarter of 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.Both studies will assess safety, tolerability, preliminary clinical activity and exploratory circulating tumor DNA and PD-L1 biomarkers.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Cohort expansion is conditional on no dose-limiting toxicities being observed in the first cohort.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, Washington, Nov. 10, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including colorectal cancer (CRC) and metastatic triple-negative breast cancer (mTNBC), today announced that leronlimab will be evaluated in two new mTNBC regimens within the Quantum Leap Healthcare Collaborative’s (QLHC) PRE-I-SPY Phase 1-1b platform study, with enrollment expected to begin shortly.
The two studies will evaluate leronlimab in distinct immunotherapy-based combinations, each incorporating a PD-1 inhibitor. PRE5 will evaluate leronlimab alongside Merck's pembrolizumab and the antibody-drug conjugate sacituzumab, while PRE7 will evaluate leronlimab in combination with Akeso's penpulimab and the standard chemotherapy agents gemcitabine and carboplatin. Both studies are designed to assess safety and tolerability in earlier-line metastatic treatment settings while exploring preliminary signals of clinical activity.
“These studies represent an important opportunity to further investigate the potential of CCR5 inhibition as part of combination treatment strategies for patients with metastatic triple-negative breast cancer,” said Jacob Lalezari, M.D., Head of Research and Translational Sciences at CytoDyn. “By evaluating leronlimab alongside different immunotherapy-based regimens and incorporating exploratory biomarker analyses, we hope to gain a better understanding of its potential role in modulating the tumor microenvironment and informing future treatment approaches for patients with this aggressive disease.”
mTNBC is an aggressive form of breast cancer characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression, limiting the applicability of several targeted treatment approaches used in other breast cancer subtypes. The two Phase 1 studies will evaluate leronlimab in combination with established treatment regimens and will incorporate exploratory biomarker assessments, including circulating tumor DNA (ctDNA) and PD-L1 expression, to generate early insights that may help inform subsequent clinical development.
“There remains a need to better understand how novel combination strategies can improve treatment for patients with metastatic triple-negative breast cancer,” said Paula Pohlmann, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center and principal investigator for both studies. “PRE-I-SPY allows us to evaluate safety while simultaneously examining biological markers that may provide an early indication of how these treatment combinations are affecting the disease.”
PRE-I-SPY Study Design and Patient Populations
Both studies will primarily evaluate the safety and tolerability of leronlimab-containing combinations while assessing preliminary signals of clinical activity and exploratory biomarkers, including ctDNA and PD-L1 expression as measured by combined positive score (CPS).
PRE5 will primarily enroll patients receiving first- or second-line treatment, while PRE7 will focus on patients receiving second-line treatment. Both studies will include patients with a CPS of less than 10.
Both study arms will use a de-escalation design that starts at the highest dose of leronlimab (700mg) and evaluates dose reductions based on a one-cycle, 21-day dose-limiting toxicity (DLT) observation period. Cohorts will include six patients each and are designed to potentially expand if no DLTs are observed in the first cohort.
PRE-I-SPY is a Phase 1 platform study designed to efficiently evaluate the safety and optimal dosing of new therapeutic agents and combinations for breast cancer. QLHC is the sponsor of the PRE-I-SPY platform study, while CytoDyn is providing leronlimab for evaluation in the two new regimens.
“An important goal of PRE-I-SPY is to identify promising therapeutic combinations with acceptable safety profiles that could potentially be evaluated in earlier-stage, high-risk breast cancer through the I-SPY 2.2 platform,” said Laura Esserman, M.D., Co-founder of QLHC and Principal Investigator of the I-SPY 2 platform.
Preparations are already underway for both studies, and enrollment for PRE5 is expected to begin in the first quarter of calendar 2027. Enrollment for PRE7 is likely to begin in the second or third quarter of calendar 2027. Additional information and updates on both studies will be provided in future Company communications.
About Quantum Leap Healthcare Collaborative
Quantum Leap Healthcare Collaborative (QLHC) is a 501c(3). It is a nonprofit pioneer that designs, implements, and succeeds at building and iterating creative and nimble solutions that drive meaningful results for patients. QLHC’s mission is to better serve patients by accelerating and innovating health care through approaches that challenge the status quo of science and care. QLHC’s efforts focus on achieving our long-term vision to improve human health for all through personalized medicine by bridging the gap between research and care. QLHC provides operational, financial, and regulatory oversight to I-SPY.
For more information, visit https://www.quantumleaphealth.org/.
About CytoDyn
CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.
For more information, please visit www.cytodyn.com and follow us on LinkedIn.
Note Regarding Forward-Looking Statements
This news release may contain forward-looking statements relating to, among other things, mechanism of action, clinical development programs, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2026, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.
Corporate Contact
CytoDyn Inc.
ir@cytodyn.com
Media Contacts
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
CytoDyn@russopartnersllc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will enrollment begin in CytoDyn’s PRE5 and PRE7 leronlimab studies?
CytoDyn expects PRE5 enrollment to begin in the first quarter of calendar 2027, while PRE7 enrollment is likely to begin in the second or third quarter of calendar 2027. Preparations for both studies are underway.
How will CytoDyn’s PRE-I-SPY studies evaluate leronlimab dosing?
Both study arms will start at the highest leronlimab dose of 700mg and evaluate dose reductions using a one-cycle, 21-day observation period for dose-limiting toxicity, meaning toxicity that limits dosing. Each cohort will include six patients, with potential expansion if no dose-limiting toxicities occur in the first cohort.